Fate Therapeutics, Inc.
2.44USD
-0.0600 (-2.40%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 3 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -31 | -33 | -35 | -35 | -37 | -41 | -62 | -52 |
| Net Income | -30 | -31 | -32 | -32 | -34 | -38 | -52 | -48 |
| EPS (Diluted) | $-0.25 | $-0.26 | $-0.27 | $-0.27 | $-0.29 | $-0.32 | $-0.45 | $-0.40 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)